Cereno Scientific appoints Eva Jagenheim as Chief Financial Officer (CFO)
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that Eva Jagenheim is appointed Chief Financial Officer (CFO). Jagenheim has broad experience in finance and the Swedish biotech sector. She will join the company on August 28, 2023.
"We are excited to welcome Eva to the Cereno team. She brings a wealth of experience and valuable financial expertise from previous roles in public biotech companies," said Sten R. Sörensen, CEO of Cereno.
Eva Jagenheim, born 1966, has an M.Sc. in Business and Economics from Växjö University and an MBA from Gothenburg Business School. She has a broad experience of various roles within finance. Previous experience includes working as an accountant at PWC, consultant at the accounting firm Arthur Andersen, and at companies of varying sizes across several different industries. She most recently work as CFO at RLS Global, a medtech company listed on Nasdaq First North Growth Market.
"I am thrilled to join Cereno at such an exciting time in its journey. The opportunity to contribute to the development of life-changing treatments for cardiovascular disease is truly inspiring. I am eager to leverage my financial expertise and strategic insights to support the company's growth and maximize value for our shareholders," said Eva Jagenheim, incoming CFO of Cereno.
For further information, please contact:
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, ﬁbrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.